Holen Sie sich die Stockscreener-App
9.5074
1.28%
0.0974
Schlusskurs vom Vortag:
$9.41
Offen:
$9.61
24-Stunden-Volumen:
47,946
Relative Volume:
0.03
Marktkapitalisierung:
$85.78M
Einnahmen:
$23.14M
Nettoeinkommen (Verlust:
$-9.47M
KGV:
-10.77
EPS:
-0.8827
Netto-Cashflow:
$-25.88M
1W Leistung:
-9.06%
1M Leistung:
+90.98%
6M Leistung:
-27.91%
1J Leistung:
+36.14%
1-Tages-Spanne:
$9.00
$9.63
1-Wochen-Bereich:
$8.54
$10.80
52-Wochen-Spanne:
$3.92
$19.14
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Firmenname
Atara Biotherapeutics Inc
Sektor
Branche
Telefon
805-623-4211
Adresse
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
9.52 | 82.44M | 23.14M | -9.47M | -25.88M | -0.8827 |
VRTX
Vertex Pharmaceuticals Inc
|
430.19 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
647.20 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.21 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.46 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.33 | 30.69B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-11-09 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-07-20 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-07-13 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Herabstufung | Stifel | Buy → Hold |
| 2022-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-05-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-30 | Eingeleitet | Evercore ISI | Outperform |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-23 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Herabstufung | Goldman | Neutral → Sell |
| 2019-09-16 | Herabstufung | Jefferies | Buy → Hold |
| 2019-06-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-05-30 | Eingeleitet | ROTH Capital | Buy |
| 2019-05-23 | Eingeleitet | Stifel | Buy |
| 2019-01-23 | Eingeleitet | Mizuho | Buy |
| 2018-04-10 | Eingeleitet | JP Morgan | Overweight |
| 2018-03-16 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-05 | Bestätigt | Jefferies | Buy |
| 2018-02-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-01-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten
Atara Biotherapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your RightsATRA - PR Newswire
FinancialContentDeadline Soon: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - FinancialContent
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
ATARA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. ... - Caledonian Record
ATARA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages - GlobeNewswire
ATARA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Atara Biotherapeutics Raised to Hold From Sell by Freedom Broker - Moomoo
Atara Biotherapeutics Price Target Raised to $10.00/Share From $4.00 by Freedom Broker - Moomoo
ATRA UPCOMING DEADLINE : The Gross Law Firm Alerts Atara Biotherapeutics, Inc. Stockholders of Securities Class ActionContact the Firm - PR Newswire
Class Action Litigation Filed by Pomerantz LLP for Investors of Atara Biotherapeutics, Inc. – ATRA - ACCESS Newswire
ATRA Upgraded by Freedom Broker -- Price Target Raised to $10 - GuruFocus
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit - The Killeen Daily Herald
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATARA DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, - GlobeNewswire
[144] Atara Biotherapeutics, Inc. SEC Filing - Stock Titan
Company (NASDAQ: ATRA) RSU Settlement and 2,104-Share Sale - Stock Titan
Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) - GlobeNewswire
DEADLINE ALERT for LU, ATRA, and COTY: The Law Offices of - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Freedom Broker upgrades Atara Biotherapeutics stock rating on FDA meeting progress - Investing.com
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit ... - Caledonian Record
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
Class Action Litigation Filed by Pomerantz LLP Concerning Atara Biotherapeutics, Inc. – ATRA - ACCESS Newswire
Trading Systems Reacting to (ATRA) Volatility - Stock Traders Daily
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Atara Biotherapeutics (NASDAQ:ATRA) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
The Gross Law Firm Reminds Atara Biotherapeutics, Inc. Investors of the Pending Class Action ... - Caledonian Record
The Gross Law Firm Reminds Atara Biotherapeutics, Inc. - GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain OfficersATRA - ChartMill
Redmile funds disclose 9.9% Atara Biotherapeutics (ATRA) stake via warrants cap - Stock Titan
ATRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
ATARA DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, - GlobeNewswire
ATRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - PR Newswire
Manufacturing and Supply-Chain Risks Threaten Atara Biotherapeutics’ Cell Therapy Pipeline - TipRanks
Atara Biotherapeutics (ATRA) to Release Earnings on Thursday - MarketBeat
8-K: Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progressmoomoo - Moomoo
Atara Biotherapeutics | 424B5: Prospectus - Moomoo
Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress - The National Law Review
Adage and principals report 8.56% stake in Atara (NASDAQ: ATRA) - Stock Titan
Atara Biotherapeutics: Runway Into Mid-2027 >ATRA - Moomoo
Atara Biotherapeutics (ATRA) Eps Diluted (TTM) - Zacks Investment Research
Atara (ATRA) Provides Update on BLA Resubmission and Financial S - GuruFocus
Atara Biotherapeutics 1Q Loss/Shr 29c >ATRA - Moomoo
Atara BiotherapeuticsMay Offer Up To $79.27 Million In Common Stock As Of May 12, 2026SEC Filing - TradingView
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Dead - GuruFocus
Atara Biotherapeutics: Q1 Earnings Snapshot - Barchart.com
Atara Biotherapeutics (NASDAQ: ATRA) adds $79.27M to ATM sales agreement - Stock Titan
Atara Biotherapeutics (NASDAQ: ATRA) Q1 2026 loss, cash strain and going concern warning - Stock Titan
Finanzdaten der Atara Biotherapeutics Inc-Aktie (ATRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
10.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):